All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

NVG-111 Generates Early Efficacy With Manageable Safety in Relapsed/Refractory CLL, MCL

September 14th 2022

The ROR1-targeting bispecific T-cell engager NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

A Primer for New Fellows

September 14th 2022

Jill Gilbert, MD, offers advice for the start of a new fellowship in oncology and hematology.

HRQoL Proves to Be Helpful Prognostic Factor for Cabozantinib/Nivolumab in Advanced RCC

September 14th 2022

Higher baseline and longitudinal evaluations of health-related quality of life prior to and during treatment with nivolumab and cabozantinib demonstrated an association with improved progression-free survival and overall survival in patients with advanced, treatment-naïve renal cell carcinoma.

Florida Cancer Specialists & Research Institute Welcomes Shivtaj Mann, DO, to Fort Myers Cancer Center

September 14th 2022

Florida Cancer Specialists & Research Institute welcomes Board-certified hematologist/oncologist Shivtaj Mann, DO, to the statewide practice.

Benchmarks in Clinical Trial Design Require Closer Examination by Oncologists

September 14th 2022

Maurie Markman, MD, elaborates on the need to take a closer look at the benchmarks used in clinical trial designs in oncology.

Brexu-cel Elicits Sustained 3-Year Responses in Relapsed/Refractory MCL

September 14th 2022

Treatment with brexucabtagene autoleucel drove durable responses in patients with relapsed/refractory mantle cell lymphoma, particularly those with minimal residual disease negativity at 6 months.

FDA and EU Approval Sought for Rucaparib as Frontline Maintenance in Select Advanced Ovarian Cancer

September 13th 2022

A supplemental new drug application and a Type II variation has been submitted to the FDA and the European Medicines Agency, respectively, seeking the approval of rucaparib as frontline maintenance treatment in women with advanced ovarian cancer irrespective of biomarker status who have responded to first-line platinum-based chemotherapy.

PSA Decline After Lutetium Lu 177 Vipivotide Tetraxetan Treatment Prolongs Survival in PSMA-Positive mCRPC

September 13th 2022

The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Pemigatinib Represents Transformative Treatment for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

September 13th 2022

Srdan Verstovsek, MD, PhD, discusses the clinical implications of the FDA approval of pemigatinib, the results of the FIGHT-203 trial, and the need to conduct chromosomal analysis for patients with myeloid/lymphoid neoplasms.

TAS-102/Bevacizumab Combo Improves OS Over TAS-102 Alone in Refractory mCRC

September 13th 2022

The addition of bevacizumab to trifluridine/tipiracil resulted in a statistically significant improvement in overall survival over trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer after 2 chemotherapy regimens.

Late Effects Arise Irrespective of High-Dose Chemotherapy and ASCT Status in MCL

September 13th 2022

Intensive first-line treatment with high-dose chemotherapy and autologous stem cell transplant was not associated with higher rates of late effects compared with outcomes from less intensive therapies in patients with mantle cell lymphoma.

Fox Chase Researchers Discover How Pancreatic Cancer Cells Manage to Survive in Poor Nutritional Environments

September 13th 2022

In a recent study, researchers at Fox Chase Cancer Center demonstrated how cancer cells can survive in the body even when faced with a lack of sufficient nutrition, a finding that could be used as a potential indicator of disease status in the organs of pancreatic cancer patients.

Obinutuzumab/Acalabrutinib/Venetoclax Triplet Misses the Mark in Relapsed/Refractory CLL

September 13th 2022

Obinutuzumab, acalabrutinib, and venetoclax following optimal debulking with bendamustine failed to meet the prespecified rate of undetectable minimal residual disease in the peripheral blood at the end of induction treatment in patients with relapsed/refractory chronic lymphocytic leukemia.

FDA Grants Orphan Drug Designation to DUNP19 for Osteosarcoma

September 13th 2022

The FDA has granted an orphan drug designation to DUNP19 for the treatment of osteosarcoma.

Lenvatinib/Pembrolizumab Combo Proves Safe, Effective for Metastasized Anaplastic and Poorly Differentiated Thyroid Carcinoma

September 13th 2022

The combination of lenvatinib and pembrolizumab was found to induce high response rates, including long-lasting remissions, and have acceptable safety in patients with metastasized anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma.

First-line Lenvatinib Plus Pembrolizumab Elicits Antitumor Activity in Non–Clear Cell RCC

September 12th 2022

Frontline lenvatinib plus pembrolizumab displayed a promising overall response rate and disease control rate in patients with non–clear cell renal cell carcinoma.

PRMT5 Inhibitor Exhibits Efficacy and Tolerability in NHL, Advanced Solid Tumors

September 12th 2022

GSK3326595, a PRMT5 inhibitor, displayed modest efficacy and safety signals that were consistent with those that were previously reported with the agent among patients with advanced solid tumors.

Adagrasib With or Without Cetuximab Elicits Responses in Advanced KRAS G12C–Mutated CRC

September 12th 2022

Adagrasib monotherapy and in combination with cetuximab generated encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

Ribociclib Plus Endocrine Therapy Provides Survival Benefit in Advanced HR+/HER2- Breast Cancer With Visceral Metastases

September 12th 2022

Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.

HRQOL Outcomes in TNBC Are Not Negatively Affected by Pembrolizumab

September 12th 2022

An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.